The FDA has approved Rezdiffra, the first medication for severe non-alcoholic fatty liver disease, showing improvement in liver scarring in NASH patients. NASH affects millions, linked to health issues like high blood pressure and diabetes. Rezdiffra targets root causes of NASH, with common side effects of diarrhoea and nausea.
The FDA has approved Rezdiffra, the first medication for severe non-alcoholic fatty liver disease, showing improvement in liver scarring in NASH patients. NASH affects millions, linked to health issues like high blood pressure and diabetes. Rezdiffra targets root causes of NASH, with common side effects of diarrhoea and nausea.
टिप्पणियाँ
एक टिप्पणी भेजें